ArticleInfection and drug resistance2025
Real-World Effectiveness of Nirmatrelvir/Ritonavir in Hospitalized Older Adults with Severe Omicron COVID-19: A Retrospective Cohort Study from China.
Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nirmatrelvir/ritonavir reduced mortality in severe or critical COVID-19 patients: a multicenter retrospective cohort study.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The real-world effectiveness of Nirmatrelvir/ritonavir (NMV/RTV) against the SARS-CoV-2 Omicron variant in older patients remains uncertain. We aimed to estimate the effectiveness in older patients aged 80 and above with severe COVID-19. Methods: A retrospective study analyzed 263 COVID-19 patients aged 80 and above, admitted to the Department of Geriatrics at Jinling Hospital, affiliated with Nanjing University, between December 15, 2022, and January 15, 2023. Among them, 136 cases were non-severe, and 127 were severe. The severe cases were further categorized into a survival group (n=74) and a death group (n=53) based on 28-day mortality. Kaplan-Meier survival curves assessed 28-day survival, and Cox regression models identified factors influencing survival. Results: Among the 127 severe cases, the death group had significantly higher rates of stroke history, renal impairment, endotracheal intubation, renal replacement therapy (RRT), bacterial infection, but significantly lower rates of NMV/RTV use and anticoagulation (p<0.05). Kaplan-Meier analysis indicated that NMV/RTV improved 28-day survival in severe older COVID-19 patients. Multivariate Cox regression identified NMV/RTV as a protective factor (adjusted hazard ratio [HR] 0.307, 95% confidence interval [ Conclusion: NMV/RTV may improve the 28-day survival rate of older patients aged 80 and above with severe COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.